InvestorsHub Logo
Followers 13
Posts 1020
Boards Moderated 0
Alias Born 07/19/2013

Re: None

Thursday, 03/02/2017 8:33:00 PM

Thursday, March 02, 2017 8:33:00 PM

Post# of 121
"In 2017 and beyond we will continue to simplify and reshape the company," Chief Executive Oliver Brandicourt told journalists. "We will be supported by our current growth engine businesses: Sanofi Genzyme, vaccines and consumer healthcare".

http://finance.yahoo.com/news/drugmaker-sanofi-sees-weak-2017-082546194.html



The keyword is SIMPLIFY and that's exactly the partnership is all about. IMO, Sanofi is aiming of simplifying the old and traditional method of making their virus-based vaccines to reduce costs as well as improving effectiveness of their vaccines not to mention the broad range application of Mymetics' virosome-based VLP platform.

Is Mymetics the next acquisition target?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNY News